Literature DB >> 3721502

Apolipoprotein E3-Leiden. A new variant of human apolipoprotein E associated with familial type III hyperlipoproteinemia.

L Havekes, E de Wit, J G Leuven, E Klasen, G Utermann, W Weber, U Beisiegel.   

Abstract

A variant of apolipoprotein E, denoted apo E3-Leiden, has been identified in a 41-year-old male suffering from type III hyperlipoproteinemia with xanthomatosis. Apo E3-Leiden focus in the E3 position. In contrast with normal apo E3, apo E3-Leiden is defective in binding to the low density lipoprotein (LDL) receptor and does not contain cysteine as evaluated by cysteamine treatment of very low density lipoprotein followed by isoelectric focusing and conventional protein staining and by amino acid analysis. On sodium dodecyl sulfate polyacrylamide gel electrophoresis, apo E3-Leiden displays an electrophoretic mobility intermediate to that of normal apo E3 and apo E2 (Arg158----Cys). The mother and four siblings of the proband also have apo E3-Leiden and hyperlipoproteinemia type III; three of them with xanthomatosis. Two siblings do not show apo E3-Leiden in their VLDL fraction and do not have hyperlipoproteinemia type III. In the VLDL fractions of all affected family members only the presence of apo E3-Leiden could be detected after cysteamine treatment and isoelectric focusing followed by conventional protein staining. However, isoelectric focusing of cysteamine-treated sera followed by immunoblotting, using anti-apo E antiserum as first antiserum, demonstrates the presence of low amounts of normal apo E3 in addition to apo E3-Leiden in serum of the affected family members. These results indicate that all affected family members are heterozygotes E3/E3-Leiden and suggest that in this family type III hyperlipoproteinemia is transmitted as a dominant trait.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3721502     DOI: 10.1007/bf00291607

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  26 in total

1.  Separation of plasma lipoproteins by density-gradient ultracentrifugation.

Authors:  T G Redgrave; D C Roberts; C E West
Journal:  Anal Biochem       Date:  1975-05-12       Impact factor: 3.365

2.  Release of low density lipoprotein from its cell surface receptor by sulfated glycosaminoglycans.

Authors:  J L Goldstein; S K Basu; G Y Brunschede; M S Brown
Journal:  Cell       Date:  1976-01       Impact factor: 41.582

3.  Polymorphism of apolipoprotein E. II. Genetics of hyperlipoproteinemia type III.

Authors:  G Utermann; K H Vogelberg; A Steinmetz; W Schoenborn; N Pruin; M Jaeschke; M Hees; H Canzler
Journal:  Clin Genet       Date:  1979-01       Impact factor: 4.438

4.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

5.  Human apolipoprotein E. The complete amino acid sequence.

Authors:  S C Rall; K H Weisgraber; R W Mahley
Journal:  J Biol Chem       Date:  1982-04-25       Impact factor: 5.157

6.  Rapid hepatic clearance of the canine lipoproteins containing only the E apoprotein by a high affinity receptor. Identity with the chylomicron remnant transport process.

Authors:  B C Sherrill; T L Innerarity; R W Mahley
Journal:  J Biol Chem       Date:  1980-03-10       Impact factor: 5.157

7.  Normalization of receptor binding of apolipoprotein E2. Evidence for modulation of the binding site conformation.

Authors:  T L Innerarity; K H Weisgraber; K S Arnold; S C Rall; R W Mahley
Journal:  J Biol Chem       Date:  1984-06-10       Impact factor: 5.157

8.  Functionally inactive apolipoprotein E3 in a type III hyperlipoproteinaemic patient.

Authors:  L M Havekes; J A Gevers Leuven; E van Corven; E de Wit; J J Emeis
Journal:  Eur J Clin Invest       Date:  1984-02       Impact factor: 4.686

9.  A new isoform of apolipoprotein E--apo E-5--associated with hyperlipidemia and atherosclerosis.

Authors:  T Yamamura; A Yamamoto; K Hiramori; S Nambu
Journal:  Atherosclerosis       Date:  1984-02       Impact factor: 5.162

10.  Familial dysbetalipoproteinemia. Abnormal binding of mutant apoprotein E to low density lipoprotein receptors of human fibroblasts and membranes from liver and adrenal of rats, rabbits, and cows.

Authors:  W J Schneider; P T Kovanen; M S Brown; J L Goldstein; G Utermann; W Weber; R J Havel; L Kotite; J P Kane; T L Innerarity; R W Mahley
Journal:  J Clin Invest       Date:  1981-10       Impact factor: 14.808

View more
  21 in total

1.  The APO(*)E3-Leiden mouse as an animal model for basal laminar deposit.

Authors:  M Kliffen; E Lutgens; M J Daemen; E D de Muinck; C M Mooy; P T de Jong
Journal:  Br J Ophthalmol       Date:  2000-12       Impact factor: 4.638

Review 2.  Animal models of age related macular degeneration.

Authors:  Mark E Pennesi; Martha Neuringer; Robert J Courtney
Journal:  Mol Aspects Med       Date:  2012-06-15

Review 3.  Indications for lipid-lowering drugs.

Authors:  J Davignon
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 4.  Vaccination against atherosclerosis.

Authors:  Kouji Kobiyama; Ryosuke Saigusa; Klaus Ley
Journal:  Curr Opin Immunol       Date:  2019-03-29       Impact factor: 7.486

5.  A novel ARH splice site mutation in a Mexican kindred with autosomal recessive hypercholesterolemia.

Authors:  Samuel Canizales-Quinteros; Carlos A Aguilar-Salinas; Adriana Huertas-Vázquez; María L Ordóñez-Sánchez; Maribel Rodríguez-Torres; José L Venturas-Gallegos; Laura Riba; Salvador Ramírez-Jimenez; Rocío Salas-Montiel; Giovani Medina-Palacios; Ludivina Robles-Osorio; Angel Miliar-García; Luis Rosales-León; Blanca H Ruiz-Ordaz; Alejandro Zentella-Dehesa; Adrian Ferré-D'Amare; Francisco J Gómez-Pérez; Ma Teresa Tusié-Luna
Journal:  Hum Genet       Date:  2004-11-17       Impact factor: 4.132

6.  Apolipoprotein E polymorphism in The Netherlands and its effect on plasma lipid and apolipoprotein levels.

Authors:  M Smit; P de Knijff; M Rosseneu; J Bury; E Klasen; R Frants; L Havekes
Journal:  Hum Genet       Date:  1988-11       Impact factor: 4.132

7.  Apolipoprotein E2-Christchurch (136 Arg----Ser). New variant of human apolipoprotein E in a patient with type III hyperlipoproteinemia.

Authors:  M R Wardell; S O Brennan; E D Janus; R Fraser; R W Carrell
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

8.  Characterization of five new mutants in the carboxyl-terminal domain of human apolipoprotein E: no cosegregation with severe hyperlipidemia.

Authors:  A M van den Maagdenberg; W Weng; I H de Bruijn; P de Knijff; H Funke; A H Smelt; J A Gevers Leuven; F M van't Hooft; G Assmann; M H Hofker
Journal:  Am J Hum Genet       Date:  1993-05       Impact factor: 11.025

Review 9.  Apolipoprotein E mutations: a comparison between lipoprotein glomerulopathy and type III hyperlipoproteinemia.

Authors:  Akira Matsunaga; Takao Saito
Journal:  Clin Exp Nephrol       Date:  2014-02-26       Impact factor: 2.801

10.  Variable expression of familial dysbetalipoproteinemia in apolipoprotein E*2 (Lys146-->Gln) Allele carriers.

Authors:  P de Knijff; A M van den Maagdenberg; D I Boomsma; A F Stalenhoef; A H Smelt; J J Kastelein; A D Marais; R R Frants; L M Havekes
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.